ARTICLE | Company News
Newco Milo debuts to develop muscular dystrophy treatment
February 17, 2012 1:40 AM UTC
Milo Biotechnology LLC (Cleveland, Ohio) raised $250,000 in seed funding from the not-for-profit JumpStart Inc. The newco's lead product, AAV1-FS, is an adeno-associated virus (AAV) vector used to deliver follistatin. Follistatin is a protein that inhibits the activity of myostatin, which impedes muscle differentiation and growth. Milo has an exclusive license to the product from Nationwide Children's Hospital. ...